Clinical Trial Update: Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the influence of genetic polymorphisms on response to osmotic-release methylphenidate in attention-deficit/hyperactivity disorder; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Concerta (OROS-Methylphenidate) (methylphenidate hydrochloride (OROS formulation))

Snippet

Sponsor: Bundang CHA Hospital | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED